18889881171
Kalkine 0
countryflagUS
Kalkine Login

AAPL 218.58 -2.3543% MSFT 378.24 -3.1594% NVDA 109.935 -1.3416% GOOGL 154.82 -4.5735% GOOG 156.57 -4.577% AMZN 192.305 -4.4969% META 576.1 -4.3944% AVGO 167.395 -2.6717% LLY 819.22 -0.2982% TSLA 262.925 -3.7363% TSM 165.41 -1.6821% V 343.52 -1.8122% JPM 241.76 -2.5633% UNH 517.77 0.3975% NVO 69.44 -1.0262% WMT 84.94 -0.8058% LVMUY 126.47 -0.3546% XOM 117.52 -0.3139% LVMHF 638.0 0.157% MA 542.47 -2.7082%
AAPL 218.58 -2.3543% MSFT 378.24 -3.1594% NVDA 109.935 -1.3416% GOOGL 154.82 -4.5735% GOOG 156.57 -4.577% AMZN 192.305 -4.4969% META 576.1 -4.3944% AVGO 167.395 -2.6717% LLY 819.22 -0.2982% TSLA 262.925 -3.7363% TSM 165.41 -1.6821% V 343.52 -1.8122% JPM 241.76 -2.5633% UNH 517.77 0.3975% NVO 69.44 -1.0262% WMT 84.94 -0.8058% LVMUY 126.47 -0.3546% XOM 117.52 -0.3139% LVMHF 638.0 0.157% MA 542.47 -2.7082%

Sinovac Biotech Ltd

Healthcare US SVA

6.47USD
-(-%)

Last update at 2025-03-27T13:30:00Z

Day Range

6.476.47
LowHigh

52 Week Range

6.476.47
LowHigh

Fundamentals

  • Previous Close 6.47
  • Market Cap642.44M
  • Volume0
  • P/E Ratio6.66
  • Dividend Yield-%
  • EBITDA219.50M
  • Revenue TTM510.62M
  • Revenue Per Share TTM5.16
  • Gross Profit TTM 443.44M
  • Diluted EPS TTM0.97

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-310M2000M4000M6000M8000M10000M12000M14000M16000M18000M
Total Revenue
Net Income

Balancesheet

2018-12-312019-12-312020-12-312021-12-312022-12-310M2000M4000M6000M8000M10000M12000M14000M16000M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-6000M-4000M-2000M0M2000M4000M6000M8000M10000M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-2000M0M2000M4000M6000M8000M10000M12000M14000M16000M

Dividends Paid

2018-12-312019-12-312020-12-312021-12-312022-12-31-1800M-1600M-1400M-1200M-1000M-800M-600M-400M-200M0M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 25.24M 17563.04M 216.62M 70.82M 46.58M
Minority interest 25.73M -5991.43100M 373.65M 58.18M 38.49M
Net income 88.13M 14458.91M 185.18M 65.22M 21.78M
Selling general administrative 823.54M 591.17M 176.53M 121.16M 137.82M
Selling and marketing expenses - - - - -
Gross profit 808.30M 18302.68M 443.44M 213.58M 204.93M
Reconciled depreciation 156.60M 86.83M 4.04M 4.82M 5.14M
Ebit 31.71M 17553.26M 215.64M 68.56M 47.73M
Ebitda 188.31M 17653.69M 222.27M 76.58M 52.86M
Depreciation and amortization 156.60M 100.43M 6.63M 8.02M 5.14M
Non operating income net other - - - - 0.00000M
Operating income 31.71M 17553.26M 215.64M 68.56M 45.32M
Other operating expenses 1953.62M 1820.67M 294.82M 177.20M 184.26M
Interest expense 1.26M 2.84M 1.45M 0.65M 1.07M
Tax provision -62.89300M 3104.13M 31.44M 5.61M 10.47M
Interest income 190.82M 102.57M 1.93M 1.35M 0.95M
Net interest income 189.55M 99.73M 0.48M 1.35M 0.95M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -62.89300M 3104.13M 31.44M 5.61M 10.47M
Total revenue 1492.76M 19374.90M 510.62M 246.05M 229.65M
Total operating expenses 1269.16M 748.45M 227.64M 144.73M 159.54M
Cost of revenue 684.46M 1072.22M 67.18M 32.47M 24.72M
Total other income expense net -6.47700M 9.78M 0.97M 2.26M 0.25M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 88.13M 14458.91M 185.18M 65.22M 36.11M
Net income applicable to common shares - - 104.35M 39.80M 21.78M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 14114.57M 16748.17M 1901.33M 452.30M 369.78M
Intangible assets 79.51M 41.21M 9.72M 7.96M 8.30M
Earning assets - - - - -
Other current assets 95.87M 171.89M 24.74M 5.03M 4.54M
Total liab 1401.91M 2872.16M 781.20M 100.10M 77.85M
Total stockholder equity 8921.42M 9327.43M 746.47M 294.02M 253.43M
Deferred long term liab - - - - 0.00000M
Other current liab 141.99M 2246.69M 46.41M 7.03M 44.46M
Common stock 0.10M 0.10M 0.10M 0.10M 0.07M
Capital stock 0.12M 0.12M 0.11M 0.11M -
Retained earnings 7225.99M 7141.82M 144.24M 56.73M 23.82M
Other liab - - 7.82M 5.71M 9.05M
Good will - - - - 0.00000M
Other assets - - 55.35M 21.75M 14.69M
Cash 4278.12M 11608.85M 1041.01M 152.72M 158.17M
Cash and equivalents - - - - -
Total current liabilities 1091.63M 2412.85M 679.61M 87.20M 58.20M
Current deferred revenue 33.08M 92.50M 379.16M 8.20M 4.89M
Net debt -4203.45100M -11463.94800M -904.62200M -132.44700M -144.25400M
Short term debt 10.64M 15.07M 42.61M 13.08M 3.32M
Short long term debt 4.65M 4.68M 39.10M 12.54M 3.32M
Short long term debt total 74.67M 144.91M 136.39M 20.27M 13.92M
Other stockholder equity 540.58M 540.58M 531.82M 207.96M 205.00M
Property plant equipment - - 284.20M 80.95M 70.92M
Total current assets 12126.40M 14915.11M 1560.29M 349.61M 284.18M
Long term investments 661.44M 655.84M - - 0.00000M
Net tangible assets - - 744.98M 294.00M 253.43M
Short term investments 7034.57M 1806.45M 135.25M 50.27M 18.91M
Net receivables 609.49M 952.40M 253.49M 113.74M 77.46M
Long term debt 11.51M 17.38M 8.29M 1.44M 3.89M
Inventory 180.72M 375.51M 105.81M 27.85M 25.09M
Accounts payable 905.92M 58.59M 211.43M 58.89M 5.53M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 1154.74M 1644.92M 70.30M 29.21M 24.54M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 0.10M 0.10M 0.07M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 123.73M 0.03M 0.03M 0.02M 0.09M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 1988.17M 1833.07M 341.03M 102.69M 85.61M
Capital lease obligations 58.51M 122.85M 89.00M 6.29M 0.00000M
Long term debt total - - - 1.44M 3.89M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -5760.47000M -3023.57400M -77.12600M -42.45400M -25.26100M
Change to liabilities - - 471.11M 9.31M -7.05900M
Total cashflows from investing activities - - -204.75600M -42.45400M -25.26100M
Net borrowings - - 574.05M -1.19600M -24.98800M
Total cash from financing activities -241.39900M -1896.68000M 592.57M 1.74M 64.18M
Change to operating activities - - -14.36100M 1.40M -2.58500M
Net income 88.13M 14458.91M 185.18M 65.22M 36.11M
Change in cash -7333.38300M 10569.56M 894.33M -2.29200M 42.21M
Begin period cash flow 11619.76M 1050.20M 155.88M 158.17M 115.96M
End period cash flow 4286.38M 11619.76M 1050.20M 155.88M 158.17M
Total cash from operating activities -770.74500M 15352.54M 479.31M 39.07M 7.94M
Issuance of capital stock 0.00000M 1.03M 2.00M - -
Depreciation 156.60M 86.83M 4.04M 4.82M 5.14M
Other cashflows from investing activities - - - -31.82600M -19.64800M
Dividends paid -263.17100M -1875.89200M - - 0.00000M
Change to inventory 30.38M -334.06200M -77.73800M -3.65100M -9.41200M
Change to account receivables 289.60M -710.35500M -128.01600M -40.19100M -13.08200M
Sale purchase of stock - 20.63M - - 85.37M
Other cashflows from financing activities 26.24M 4.32M 600.95M 5.04M 22.76M
Change to netincome - - 82.11M 17.55M 25.01M
Capital expenditures 403.37M 719.98M 127.65M 10.63M 5.61M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -1081.18800M 460.62M 282.80M -28.22700M -43.98200M
Stock based compensation 0.00000M 7.74M 10.20M 3.00M 4.30M
Other non cash items 148.72M 73.35M 8.32M -0.04900M 3.23M
Free cash flow -1174.11300M 14632.56M 351.66M 28.45M 2.33M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SVA
Sinovac Biotech Ltd		 - -% 6.47 6.66 - 1.83 1.82 0.71 -0.3709
NVO
Novo Nordisk A/S		 -0.72 1.03% 69.44 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.98 1.40% 68.80 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.59 1.51% 494.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.80 0.60% 639.63 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Sinovac Biotech Ltd

No.39, SHANGDI West Road, Beijing, China, 100085

Key Executives

Name Title Year Born
Dr. Weidong Yin Chairman, CEO, Pres, MD, GM & Sec. 1965
Ms. Nan Wang CFO & VP of Bus. Devel. 1966
Mr. Qiang Gao VP & COO 1977
Mr. Ming Xia VP of Sales & Marketing 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.